Registered title, quoted from ClinicalTrials.gov
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
An open trial on myasthenia gravis, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteHuashan Hospital复旦大学附属华山医院ShanghaiHospital page
- Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07622342, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Male and female participants aged 18-75 years, confirmed diagnosis of generalized myasthenia gravis (gMG) (Myasthenia Gravis Foundation of America [MGFA] class II-IV).
Inclusion criterion 1
Myasthenic crisis (MGFA Class V) within 3 months prior to randomization;
Exclusion criterion 4
Anti-CD20 monoclonal antibody within 6 months prior to randomization; other B-cell or plasma cell-depleting therapy within 6-12 months prior to randomization;
Exclusion criterion 10
Any infection requiring hospitalization and/or intravenous antimicrobial therapy within 8 weeks prior to randomization, or any infection requiring oral antimicrobial therapy within 2 weeks prior to randomization;
Exclusion criterion 23
Major surgery within 3 months prior to the screening, or planned major surgery during the study;
Exclusion criterion 29
A history of malignancy within 5 years prior to screening;
Exclusion criterion 17
Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody, treponemal pallidum antibody, or human immunodeficiency virus (HIV) antibody; for patients with HBsAg-negative but hepatitis B core antibody (HBcAb)-positive, regardless of the status of hepatitis B surface antibody (HBsAb), HBV-DNA testing is required to confirm their condition, with HBV-DNA-positive patients excluded and HBV-DNA-negative patients eligible to participate in the study.
Exclusion criterion 24
Female subjects with fertility or male participants whose partners are women of childbearing age must avoid donating sperm/eggs from the date of signing the ICF until 12 weeks after the last study medication, and agree to take contraceptive measures as specified in the protocol
Inclusion criterion 8
Pregnant or lactating females;
Exclusion criterion 26
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07622342, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Male and female participants aged 18-75 years, confirmed diagnosis of generalized myasthenia gravis (gMG) (Myasthenia Gravis Foundation of America [MGFA] class II-IV).
- Positive for anti-AChR antibody or anti-MuSK antibody.
- MG-ADL total score ≥5 at screening and baseline, with >50% of the score attributable to non-ocular items.
- QMG score ≥11 at screening and baseline.
- Maintenance on stable standard of care (SOC) therapy.
- No contraindication to at least one rescue therapy: IVIg or PLEX.
- Provided written informed consent (ICF) after full understanding of the study content, procedures, and potential adverse reactions.
- Female subjects with fertility or male participants whose partners are women of childbearing age must avoid donating sperm/eggs from the date of signing the ICF until 12 weeks after the last study medication, and agree to take contraceptive measures as specified in the protocol
Exclusion Criteria:
- Presence of any of the following medical histories or comorbidities:
- Any untreated thymic epithelial tumor, mediastinal germ cell tumor, or other malignant mediastinal mass; or any thymic cyst or other mass requiring immediate intervention per investigator judgment;
- Previous history of thymic tumor not meeting protocol requirements;
- Myasthenic crisis (MGFA Class V) within 3 months prior to randomization;
- Any known disease other than gMG that may interfere with study procedures and assessments;
- A history of progressive multifocal leukoencephalopathy (PML);
- A history of body irradiation or organ transplantation.
- Use of any of the following drugs/treatments or participation in a clinical study:
- Prior treatment with CAR-T or other cellular therapy, or T-cell engager (TCE) therapy;
- Anti-CD20 monoclonal antibody within 6 months prior to randomization; other B-cell or plasma cell-depleting therapy within 6-12 months prior to randomization;
- Alkylating agent within 12 weeks prior to randomization;
- Any biologic for MG treatment within 12 weeks prior to randomization;
- Neonatal Fc receptor antagonist therapy within 8 weeks prior to randomization;
- Janus kinase (JAK), Bruton tyrosine kinase (BTK), or tyrosine kinase 2 (TYK2) inhibitor within 12 weeks prior to randomization;
- IVIg, subcutaneous immunoglobulin, or PLEX therapy within 4 weeks prior to randomization;
- Live/attenuated live vaccine within 4 weeks prior to randomization, or planned vaccination during the study.
- A history of malignancy within 5 years prior to screening;
- Infection-related medical history and examinations:
- A history of herpes zoster meeting any of the following: 1) A history of disseminated herpes zoster, herpes zoster encephalitis, or ocular herpes zoster involving the retina; 2) Recurrent herpes zoster with 2 or more episodes within 2 years; 3) Herpes zoster infection not fully resolved within 12 weeks prior to screening;
- A history of tuberculosis (TB) or latent TB infection;
- A known history of primary immunodeficiency, splenectomy, or any underlying condition predisposing to infection;
- A history of recurrent infections requiring hospitalization and intravenous antibiotics;
- Any infection requiring hospitalization and/or intravenous antimicrobial therapy within 8 weeks prior to randomization, or any infection requiring oral antimicrobial therapy within 2 weeks prior to randomization;
- Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody, treponemal pallidum antibody, or human immunodeficiency virus (HIV) antibody; for patients with HBsAg-negative but hepatitis B core antibody (HBcAb)-positive, regardless of the status of hepatitis B surface antibody (HBsAb), HBV-DNA testing is required to confirm their condition, with HBV-DNA-positive patients excluded and HBV-DNA-negative patients eligible to participate in the study.
- General situation:
- Pregnant or lactating females;
- A history of alcohol abuse or illicit drug abuse within 1 year prior to screening;
- A history of allergic diathesis, or known hypersensitivity/intolerance to any component of the investigational product;
- Major surgery within 3 months prior to the screening, or planned major surgery during the study;
- Any condition that, in the investigator's judgment, may affect evaluation of study drug safety and efficacy, or any other condition that renders the subject ineligible.
Quoted from ClinicalTrials.gov, NCT07622342, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07622342, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.